Author: admin

The 74^th Presidential Advisory Committee on HIV/AIDS (PACHA Council) will be taking place in Los Angeles, CA on Monday, September 19, 2022 and September 20, 2022. The meeting will be hybrid for those who wish to participate virtually. It is open to the public and everyone.

See more details below regarding times and registration information:

• When: Monday, September 19, 2022 from 4:00 – 10:00 pm (ET)/1:00 pm – 7:00 pm (PT) and September 20, 2022 from a 3:30 – 8:00 pm (ET)/12:30 pm – 5:00 pm (PT).
• Where: Martin Luther King Jr. Outpatient Building, 1670 E. 120th Street, Los Angeles, CA 90059. (The closest metro stop is the Willowbrook/Rosa Parks station.) To attend the meeting virtually, please visit www.hhs.gov/live on date and time of event.
• “PACHA-to-the-People”: PACHA wants to hear from you! There will be a Listening Session with audience attendees on September 19. This is an opportunity for our PACHA members and leaders to hear from the community. Please encourage the community to attend.
• Registration: Due to limited seating, pre-registration for individuals attending in-person is encouraged. To register, please email your name to PACHA@hhs.gov by close of business Friday, September 9, 2022.
• Public Comment: Pre-registration is required to provide public comment. To pre-register, please send an email to PACHA@hhs.gov and include your name, organization, and title by close of business Friday, September 9, 2022.
• Agenda forthcoming: The meeting agenda will be posted on the PACHA page on HIV.gov prior to the meeting. The agenda will also be sent out once it is finalized. On the second day, community partners will be invited to participate on a panel to discuss the needs of the community.

For more information, please see the Federal Register Notice: View the Notice here.

Cross-posted from hivinfo.nih.gov

The HHS Panel on the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children (the Panel) updated the following section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Highlights from the updated section are summarized below:

Monkeypox

• The Panel added a brief statement about monkeypox with links to information from the Centers for Disease Control and Prevention.
• Information about monkeypox as an HIV-related opportunistic infection in children with HIV will be added to this guideline as relevant data emerge.

For a list of recent updates, please see What’s New in the Guidelines. To view or download the guidelines, go to the Pediatric Opportunistic Infections Guidelines section of Clinical Info’s website. The guidelines tables and recommendations also can be downloaded as separate PDF files.

Clinical Info welcomes your feedback on the latest revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Please send your comments with the subject line “Pediatric Opportunistic Infection Guidelines” to HIVinfo@NIH.gov by September 23, 2022.

Cross-posted from hivinfo.nih.gov

Explore HIV and Immunization Resources for National Immunization Awareness Month

August is National Immunization Awareness Month. This annual observance highlights the importance of getting recommended vaccines. Vaccines are especially important for people with chronic health conditions like HIV, which can make it harder to fight off preventable diseases. For information about recommended vaccines for people with HIV, view the HIV and Immunizations fact sheet.

The following vaccines are recommended for people with HIV:

• Hepatitis B
• Human papillomavirus (HPV)
• Influenza (flu)
• Meningococcal
• Pneumococcal (pneumonia)
• Tetanus, diphtheria, and pertussis (whooping cough). A single vaccine called Tdap protects adolescents and adults against these three diseases.

Additional vaccines may be recommended for a person with HIV based on the person’s age, previous vaccinations, risk factors for a particular disease, or certain HIV-related factors. Learn more about immunizations for preventable diseases in adults with HIV.

People with HIV should talk with their health care providers to determine which vaccines they should receive and when they should receive them.

Testing is underway on experimental vaccines to prevent and treat HIV, but no HIV vaccines have been approved for use outside of clinical trials. For more information about experimental HIV vaccines, read the HIVinfo fact sheets What is a Preventive HIV Vaccine? and What is a Therapeutic HIV Vaccine?

Monday, August 29th 2022 is National Faith HIV/AIDS Awareness Day (NFHAAD). The event is spearheaded by RAHMA, Reaching All HIV+ Muslims in America, who held the first NFHAAD observance in 2017.

RAHMA notes that while faith plays a major role in the lives of many Americans, for many living with HIV, faith communities can turn from a place of refuge to a source of stigma and turmoil. RAHMA’s overall goal is to rally all US communities representative of the Muslim, Christian, Jewish, Buddhist, Sikh, Hindu and Baha’i faiths to take a stand against stigma in their congregations and raise awareness on HIV/AIDS.

Find Faith Awareness events near you

Hear from #NFHAAD ambassadors

Watch “My Faith, My Story”

• “My Faith, My Story,” is a short documentary-style film amplifying the voices of a few Faith Leaders, Advocates, and People Living with HIV in the South.

NFHAD 2020 Celebration

• Watch videos from the virtual NFHAAD 2020 celebration and other past observances.

Learn more about RAHMA’s work

Access the following PAETC on-demand courses for combatting stigma:

• HIV Learning Network – HIV Stigma & LGBT Communities
• HIV Learning Network – Culturally-Based Programs to Improve Engagement and Health Outcomes: Addressing Stigma for Native Hawaiian with HIV
• HIV Learning Network – HIV Status Disclosure: Considerations to reduce stigma in serodifferent relationships

The HRSA HIV/AIDS Bureau (HAB) has released the Ryan White HIV/AIDS Program (RWHAP) AIDS Drug Assistance Program (ADAP) Annual Client-Level Data Report, 2020.

This publication reflects HRSA HAB’s ongoing commitment to ensuring the availability of program information. The report is the fourth publication of national ADAP client-level data submitted through the ADAP Data Report (ADR) system. ADR data describe the demographic characteristics of clients accessing ADAP services and the ADAP-funded services used.  Data are included for 2016 through 2020, nationally and by state/territory.

The publication provides a deeper look at service utilization, demographic, and socioeconomic factors among clients served by ADAP. The report includes client-level data based on age, race/ethnicity, federal poverty level, and health care coverage.

Access this report and other tools

Cross-posted from HIV.gov

U.S. Department of Health and Human Services Secretary Xavier Becerra announced today that he will declare the ongoing spread of monkeypox virus in the United States a Public Health Emergency (PHE). This action will further strengthen and accelerate the Biden-Harris Administration’s response in recognition of the continued rapid transmission of monkeypox in the U.S. and globally, and to signal the seriousness and urgency with which the Administration is responding. The announcement comes on the heels of President Biden appointing Robert Fenton of the Federal Emergency Management Agency as White House National Monkeypox Response Coordinator and Dr. Demetre Daskalakis of the Centers for Disease Control and Prevention as White House National Monkeypox Response Deputy Coordinator.

“Ending the monkeypox outbreak is a critical priority for the Biden-Harris Administration. We are taking our response to the next level by declaring a public health emergency,” said Secretary Becerra. “With today’s declaration we can further strengthen and accelerate our response further.”

“President Biden has called on us to explore every option on the table to combat the monkeypox outbreak and protect communities at risk,” said White House National Monkeypox Response Coordinator Robert Fenton. “We are applying lessons learned from the battles we’ve fought – from COVID response to wildfires to measles, and will tackle this outbreak with the urgency this moment demands.”

The PHE declaration is in concert with the Food and Drug Administration’s (FDA) work to explore new strategies that could help get vaccines to affected communities across the country, including using new dose-sparing approach that could increase the number of doses available, up to five-fold.

The public health emergency also carries important implications for data sharing with the federal government. Fifty-one jurisdictions have already signed data use agreements that will provide the Centers for Disease Control and Prevention (CDC) with information related to vaccine administration. Declaring the outbreak an emergency may provide the justification that the remaining jurisdictions need to sign their agreements. Additionally, it provides authorities to the Centers for Medicare & Medicaid Services to collect testing and hospitalization data.

As of today, HHS has shipped more than 602,000 doses of the JYNNEOS vaccine to states and jurisdictions, an increase of 266,000 in the past week. HHS has allocated 1.1 million doses to states and jurisdictions in total and is making more doses available as jurisdictions use their current supply. HHS also announced today that it has accelerated the delivery of an additional 150,000 doses to arrive in the U.S. next month. The doses, which were slated to arrive in November will now arrive in the U.S. in September.

Today’s announcements are part of the Biden-Harris Administration’s comprehensive strategy to combat the monkeypox outbreak.  The strategy includes significantly scaling the production and availability of vaccines, expanding testing capacity and making testing more convenient, reducing burdens in accessing treatments, and conducting robust outreach to stakeholders and members of the LGBTQI+ communities.

Learn more